N-Acetyl Cysteine (NAC) is one of the most clinically studied compounds in medicine — it's been a pharmaceutical treatment for acetaminophen overdose, contrast dye nephrotoxicity, COPD, and cystic fibrosis for decades. Its entry into the supplement market created a conflict with the FDA, which in 2020 issued warning letters asserting that because NAC was studied as a drug first (in the 1960s), it could not legally be sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). That position was contested, the FDA deferred enforcement, and after a 2022 ruling period the situation remained legally ambiguous. NAC remains available in supplements from most major retailers as of mid-2026.
For consumers, the relevant question is simpler: what does the evidence show and for whom does it make sense? The answer is more nuanced than most supplement marketing suggests — NAC has excellent evidence for specific indications and weaker evidence for the generic "antioxidant support" framing that most products use.
Glutathione (GSH) is a tripeptide (glutamate + cysteine + glycine) that serves as the primary intracellular antioxidant in the body. Unlike vitamin C or vitamin E, which circulate in plasma, glutathione works inside cells — neutralizing reactive oxygen species, recycling other antioxidants, conjugating and detoxifying xenobiotics in the liver, and maintaining the intracellular redox environment. The liver is the primary site of glutathione synthesis and is most affected by depletion.
Cysteine is the rate-limiting substrate — glutamate and glycine are abundant, but cysteine availability determines how much glutathione the cell can make. NAC is an acetylated form of cysteine: the acetyl group improves stability and absorption, and is removed intracellularly to release cysteine for glutathione synthesis. Oral glutathione supplements are mostly hydrolyzed in the gut; NAC reaches systemic circulation and cells more reliably. Liposomal glutathione has somewhat better absorption than standard oral glutathione, but the evidence that it outperforms NAC in raising intracellular glutathione remains limited.
IV NAC is the standard treatment for acetaminophen (paracetamol/Tylenol) overdose — one of the most common poisonings globally. Acetaminophen is metabolized in the liver to a reactive intermediate (NAPQI) that depletes glutathione and causes hepatocyte death. NAC floods the liver with cysteine, enabling rapid glutathione resynthesis that neutralizes NAPQI before cell death occurs. If given within 8–10 hours of overdose, IV NAC prevents liver failure with >95% efficacy. This is not a supplement application but establishes the glutathione-repletion mechanism beyond any doubt.
NAC has been used as a mucolytic (mucus thinner) in respiratory medicine for decades — the free thiol group breaks disulfide bonds in mucus glycoproteins, reducing viscosity. A 2000 meta-analysis of 39 trials found NAC 600mg/day reduced acute exacerbation rates in chronic bronchitis by 23% vs. placebo. A large European trial (BRONCUS, 2005) found no benefit for lung function decline — but participants were already optimally treated and the trial wasn't powered for exacerbations. The current consensus: NAC reduces exacerbation frequency in COPD/chronic bronchitis; effect on long-term lung function is unclear.
NAC has a second mechanism beyond glutathione: it modulates the cystine-glutamate antiporter in the brain, increasing extracellular glutamate in the nucleus accumbens and prefrontal cortex. Glutamate dysregulation is implicated in OCD and addictive disorders (compulsive behavior circuits). A 2016 Cochrane-adjacent systematic review of NAC in OCD found significant benefit in 3 of 5 RCTs. A 2012 RCT (Grant et al.) found NAC 2400–3000mg/day significantly reduced gambling urges in pathological gambling. Multiple trials in cocaine, marijuana, and nicotine dependence show signal — particularly in reducing craving and use behavior. The OCD/addiction evidence uses much higher doses (1800–3000mg/day) than typical supplement use (600mg).
| Indication | Dose Used in Trials | Timing | Evidence Level |
|---|---|---|---|
| General antioxidant / liver support | 600mg/day | Once daily, with food | Reasonable but modest evidence |
| COPD / chronic bronchitis | 600mg/day | Once daily | Good — supported by meta-analysis |
| OCD / compulsive behaviors | 1800–3000mg/day | Split dosing BID or TID | Promising — specialist supervision recommended |
| Alcohol use — liver protection | 600–1200mg/day | With or around alcohol consumption | Mechanistic rationale; human trial data limited |
| Exercise recovery (oxidative stress) | 600–1200mg/day | Post-exercise | Mixed — high doses may blunt adaptation |
In July 2020, the FDA sent warning letters to several companies selling NAC as a dietary supplement, asserting that because NAC was authorized as a drug in 1963 (before DSHEA), it could not legally be marketed as a supplement. After congressional pushback and significant public comment, the FDA issued a proposed rule in 2022 to formally exclude NAC from the supplement definition — then deferred again pending further review. As of mid-2026, no final rule excluding NAC has been enacted. NAC remains available on Amazon, iHerb, and major supplement retailers. The situation could change; if you use NAC regularly, tracking FDA announcements is prudent.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.